In recent work we have shown that the pharmacological activation of the glucagon-like peptide-1 (GLP1) receptor with agonists such as liraglutide and exendin 4 protect against olanzapine induced increases in glucagon and hyperglycemia, while antagonizing the GLP1 receptor potentiates the blood glucose response to olanzapine (Medak et al., 2020). This evidence concerns the gene GLP1R and Hyperglycemia.